Phase I Trial of Sulindac plus 5-Fluorouracil and Levamisole:
Potential Adjuvant Therapy for Colon Carcinoma

Frank A. Sinicrope, Richard Pazdur, and Bernard Levin
Department of Gastrointestinal Medical Oncology and Digestive Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas 77030

ABSTRACT
Epidemiological studies indicate that nonsteroidal anti-inflammatory agents may reduce colorectal cancer incidence and mortality. Moreover, sulindac has been shown to attenuate the growth and progression of colonic neoplasms in an experimental model of colon carcinoma and in patients with familial adenomatous polyposis. To determine whether sulindac (300 mg/day) would increase toxicity associated with 5-fluorouracil (5-FU) and levamisole, 15 patients with advanced colorectal cancer were treated. Median treatment duration was 3 (range, 0.6–6.0) months, and median age was 56 years (33% > 60 years). All patients had failed prior 5-FU-based therapy, had measurable disease, and were evaluable for toxicity. Grade III/IV granulocytopenia occurred in four patients; three patients had received prior pelvic irradiation resulting in a predisposition to myelosuppression. Two patients developed grade III anemia, and occult gastrointestinal bleeding was suspected in one. No other grade II or greater gastrointestinal or other nonhematological toxicity occurred. One patient had a partial response, 3 patients had disease stabilization, and 10 patients progressed on study. Our results indicate that sulindac does not significantly increase short-term toxicity associated with 5-FU and levamisole. To determine whether sulindac increases the efficacy of adjuvant chemotherapy, we propose a phase III randomized trial in patients with lymph node-positive colon cancer.

INTRODUCTION
Adjuvant chemotherapy with 5-FU and levamisole was shown to significantly improve survival rates in patients with resected lymph node-positive (stage III) colon carcinomas (1). Attempts to improve on these results are being actively pursued. Epidemiological (2–7), clinical (8–12), and laboratory (13–19) studies indicate that NSAIDs, including sulindac, may reduce colorectal cancer incidence and mortality. Furthermore, an inverse association between aspirin intake and metastatic colorectal cancer has been reported, suggesting that aspirin may inhibit progression of established cancer (7). In patients with metastatic solid tumors including colon cancers, indomethacin was shown to significantly prolong mean survival compared to placebo (20). In support of these observations are several recent studies demonstrating that sulindac can significantly inhibit growth and attenuate progression of colorectal adenomas, precursor lesions of carcinomas, in patients with familial adenomatous polyposis (8–12). Additionally, in an experimental model of colon cancer, administration of sulindac during the postinitiation/progression phase of colon carcinogenesis significantly suppressed the incidence, size, and multiplicity of invasive and noninvasive colon adenocarcinomas (19). NSAIDs also inhibit growth of transplanted colon carcinomas in rodents (21–23) and decrease the incidence, size, and multiplicity of invasive and noninvasive colon adenocarcinomas (19). NSAIDs also inhibit growth of transplanted colon carcinomas in rodents (21–23) and decrease the incidence, size, and multiplicity of invasive and noninvasive colon adenocarcinomas (19). NSAIDs also inhibit growth of transplanted colon carcinomas in rodents (21–23) and decrease the incidence, size, and multiplicity of invasive and noninvasive colon adenocarcinomas (19).

Received 6/5/95; revised 8/20/95; accepted 8/30/95.
1 To whom requests for reprints should be addressed, at Department of Gastrointestinal Medical Oncology and Digestive Diseases, University of Texas MD Anderson Cancer Center, Box 78, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-2828; Fax: (713) 745-1163.
2 The abbreviations used are: 5-FU, 5-fluorouracil; NSAID, nonsteroidal anti-inflammatory drug; PG, prostaglandin.
Sulindac as Adjuvant Therapy of Colon Carcinoma

has been found between the NSAID dose and gastrointestinal complications (34). Given that toxic reactions observed during treatment with fluoropyrimidines are predominantly due to their effects on rapidly dividing cells, including the gastrointestinal mucosa (36), our study was designed to determine whether sulindac increases the frequency of toxic effects associated with 5-FU and levamisole.

PATIENTS AND METHODS

Fifteen patients with measurable, advanced colorectal carcinoma were enrolled in a pilot study of sulindac plus 5-FU and levamisole; characteristics of these patients are listed in Table 1. All patients had failed at least one 5-FU-based regimen and had not received chemotherapy for at least 4 weeks prior to study entry. Our aim was to treat all patients for a minimum of 2 months. Systemic 5-FU (450 mg/m²) and p.o. levamisole; characteristics of these patients are listed in Table 1. All patients had failed at least one 5-FU-based regimen and had not received chemotherapy for at least 4 weeks prior to study entry. Our aim was to treat all patients for a minimum of 2 months. Systemic 5-FU (450 mg/m²) and p.o. levamisole (Janssen Pharmaceutica, Titusville, NJ) were given in the same doses and schedules as used in the Intergroup (National Cancer Institute Cooperative Group Consortium) adjuvant trial (Ref. 1; Table 2). Sulindac (Schein Pharmaceuticals, Florham Park, NJ), 150 mg, was administered p.o. twice daily beginning on the first day of treatment. This dosage of sulindac was selected based on its demonstrated efficacy in inhibiting colorectal neoplastic growth in familial adenomatous polyposis patients (12). Patients received pretreatment and weekly serum chemistry tests, complete blood counts with differential and platelet counts, as well as chest radiographs and computed tomographic scans which were obtained at study entry and again after 2 months of therapy. Patients were seen monthly in the outpatient clinic and pill counts were performed to assess compliance. Toxicity was graded according to the National Cancer Institute common toxicity criteria. Responding patients continued therapy until disease progression occurred. None of the patients received H2 receptor antagonists, sucralfate, or misoprostol. This study was approved by the MD Anderson Cancer Center Institutional Review Board.

RESULTS

Fourteen patients were evaluable for response, and toxicity data were available on all 15 patients (Table 3). The primary tumor site was the rectum in eight patients and the colon in seven patients (Table 1). There were 10 men and 5 women; median age of the patients was 56 (range, 35–70) years, and 33% of the patients were over 60 years old. All patients had a Zubrod performance status of 0 or 1 and had a serum creatinine < 1.5 mg/dl. Furthermore, all patients had a negative stool guaiac at study entry, had not had a peptic ulcer previously, and were not currently taking aspirin or other NSAIDs. Median number of months on study was 3 (range, 0.6–6.0) months.

Leukopenia was the principal toxic reaction that led to dose limitation or patient removal from the study. In this regard, severe (grade III/IV) granulocytopenia occurred in 4 (27%) of 15 patients, 2 of whom required hospitalization for neutropenic fever and were taken out of the study (Table 3). Leukopenia generally followed induction chemotherapy and was fully reversible in all cases. Three of these four patients had received prior pelvic irradiation, and this factor, particularly pelvic irradiation in addition to prior therapy, appears to have resulted in a predisposition to myelosuppression. Two patients developed grade III anemia, and one was taken off therapy due to suspected occult gastrointestinal bleeding. This patient complained of nausea without vomiting or abdominal pain, and denied that any gross gastrointestinal bleeding had occurred. The rapidity of the fall in this patient’s hemoglobin suggested that if a gastrointestinal source was responsible, melena or hematochezia should manifest but none was observed.
Nonhematological toxicities were mild (grade 1), and no grade II or greater toxic effects occurred. Mild nausea and/or vomiting were the most frequent gastrointestinal toxic effects and were experienced by 4 (27%) of 15 patients, followed by stomatitis in 2 patients, and diarrhea and indigestion in one patient each (Table 3). No significant perturbation of hepatic, renal, or electrolyte function was noted. Compliance was assessed by pill counts at the time of monthly clinic visits and was excellent. All toxic effects were reversible, and there were no chemotherapy-related deaths. A partial response was seen in 1 patient, 3 patients had disease stabilization, and 10 patients progressed while in the study. The one objective clinical response was maintained following 5 months of treatment, as indicated by a sustained reduction in the number and size of pulmonary metastases. This patient, however, elected to discontinue further treatment given that her disease was no longer measurable.

DISCUSSION

Evidence indicates that sulindac can prevent tumor progression in an experimental colon cancer model (18, 19) and in patients with familial polyposis (8–12). These results and studies demonstrating inhibition of tumor metastasis by NSAIDs provide the rationale for a study to evaluate sulindac to eradicate micrometastatic disease. Before examining sulindac as postoperative adjuvant therapy for colon cancer, we sought to determine whether the concurrent administration of sulindac with 5-FU and levmisole would increase the incidence or severity of toxic effects, particularly those involving the gastrointestinal tract. Given that fluoropyrimidines inhibit gastrointestinal mucosal proliferation (37) and as a consequence impair mucosal repair, we were concerned that 5-FU may potentiate the sulindac-related mucosal injury. Our results indicate that toxic effects involving the gastrointestinal tract were always mild in severity. Moreover, the frequency of gastrointestinal toxic effects observed in this study was decreased compared with that produced by 5-FU and levmisole in the Intergroup adjuvant colon cancer trial (1). One cannot exclude the possibility that our patients may have been more tolerant of gastrointestinal side effects given their advanced tumor stage and prior exposure to 5-FU-based chemotherapy. Nevertheless, the relatively low incidence of adverse gastrointestinal side effects indicates that sulindac (300 mg/day) does not significantly increase short-term gastrointestinal toxicity associated with 5-FU and levmisole. The duration of treatment in this study was limited by the rapid disease progression observed in many of the patients. However, extensive evaluation of sulindac in patients with arthritic conditions has shown that the incidence of adverse effects was most frequent within the first 42 days of treatment and did not increase with extended use of sulindac. Therefore, we believe that our median treatment duration of 3 months was sufficient to assess the toxicity of this regimen.

Sulindac is a produg that is converted in the colon by bacterial microflora to its sulfone and sulfide metabolites (27).

Consistent with the fact that sulindac itself is not a cyclooxygenase inhibitor, endoscopic studies have shown that sulindac (300 mg/day) produces less gastric mucosal injury than several other NSAIDs, including aspirin, and is associated with fewer gastrointestinal symptoms than with aspirin (38, 39). However, the use of any NSAID is associated with an increased frequency of peptic ulcers and ulcer complications, including gastrointestinal bleeding (33–36). In a study of patients 65 years of age or older hospitalized for peptic ulcer disease, the relative risk of developing a peptic ulcer among users of sulindac (300 mg/day) was 4.2 (95% confidence interval, 2.8–6.3; Ref. 34). In our study, 33% of the patients were over the age of 60 years, which approximates the population receiving adjuvant chemotherapy for colon cancer.

Although none of our patients took H2 receptor antagonists or sucralfate, studies have failed to demonstrate a protective effect of these agents in the prevention of NSAID-related gastric ulcers. However, ranitidine can prevent NSAID-related duodenal ulcers (40–42). Controlled studies have shown that misoprostol produces a significant reduction in both gastric and duodenal ulcers in osteoarthritic patients taking NSAIDs on a continuous basis (43, 44). Given that misoprostol is a synthetic PGE1 analogue, it has the potential, in theory, to interfere with the antitumor properties of NSAIDs. Furthermore, this agent produces diarrhea in a significant number of patients and may thereby exacerbate diarrhea seen in patients receiving 5-FU (43). Compared with ranitidine (300 mg/day), omeprazole (40 mg/day) has been shown to produce significantly better healing of gastric ulcers despite continued use of NSAIDs (45). However, the efficacy of omeprazole in preventing NSAID-induced ulcers awaits further study.

In this study, we observed an increased frequency of severe leukopenia (27%). Three patients received prior pelvic irradiation for rectal cancer, which may explain their predisposition to leukopenia. With the exception of these three cases, leukopenia was no more frequent in our study than in patients receiving 5-FU and levmisole in the Intergroup adjuvant trial (1). Anecdotal cases of agranulocytosis and aplastic anemia attributed to sulindac have been reported (46–48). In our study, however, cases of severe leukopenia generally followed induction chemotherapy. Moreover, two of the four patients experienced recovery of their leukocyte counts despite continuous sulindac therapy which excludes sulindac as the etiological agent of their leukopenia.

Our results suggest that the addition of sulindac to 5-FU plus levmisole does not result in a significant increase in short-term toxicity and that this regimen should be well tolerated. Sufficient data regarding the antitumor properties of sulindac exist to warrant its evaluation in combination with postoperative adjuvant chemotherapy for colon cancer. Furthermore, these data appear to be more compelling than that which existed for levmisole before its incorporation into the Intergroup trial (1). We believe that the addition of sulindac to 5-FU and levmisole represents a novel approach to the adjuvant therapy of colon cancer. Therefore, we propose a phase III randomized trial to determine whether this three-drug regimen can improve survival rates in patients with resected lymph node-positive colon cancer.

3 Merck & Co., Inc., manufacturer communication.
NOTE ADDED IN PROOF

Recent evidence indicates that sulindac sulfone and sulfide can induce apoptotic cell death in cultured colon carcinoma cells, suggesting that induction of apoptosis contributes to the antitumor effects of these compounds (49). Apoptosis is a genetically regulated mechanism of cell death characterized by specific morphological and biochemical features (50, 51). Essentially all anticancer drugs, as well as radiation, kill tumor cells primarily by inducing apoptosis (50). Therefore, sulindac may induce apoptosis by utilizing a common biochemical pathway of cell death shared by conventional anticancer treatments.

REFERENCES


11. Carson, J. L., Strom, B. L., Soper, K. A., West, S. L., and Morse, M. L. Apoptosis is a genetically regulated mechanism of cell death characterized by specific morphological and biochemical features (50, 51). Essentially all anticancer drugs, as well as radiation, kill tumor cells primarily by inducing apoptosis (50). Therefore, sulindac may induce apoptosis by utilizing a common biochemical pathway of cell death shared by conventional anticancer treatments.


Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma.

F A Sinicrope, R Pazdur and B Levin


Updated version  Access the most recent version of this article at: [http://clincancerres.aacrjournals.org/content/2/1/37](http://clincancerres.aacrjournals.org/content/2/1/37)

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.